Author/Authors :
Michalska-Bańkowska, Anna Chair and Department of Dermatology - School of Medicine - Medical University of Silesia, Katowice, Poland , Wcisło-Dziadecka, Dominika Department of Skin Structural Studies - Chair of Cosmetology - School of Pharmacy with Division of Laboratory Medicine in Sosnowiec - Medical University of Silesia in Katowice, Poland , Grabarek, Beniamin Chair and Department of Molecular Biology - School of Pharmacy with Division of Laboratory Medicine in Sosnowiec - Medical University of Silesia in Katowice, Poland , Brzezińska-Wcisło, Ligia Chair and Department of Dermatology - School of Medicine - Medical University of Silesia, Katowice, Poland , Mazurek, Urszula Chair and Department of Molecular Biology - School of Pharmacy with Division of Laboratory Medicine in Sosnowiec - Medical University of Silesia in Katowice, Poland , Salwowska, Natalia ,1 and Mirosław Bańkowski4 Chair and Department of Dermatology - School of Medicine - Medical University of Silesia, Katowice, Poland
Abstract :
Introduction
Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disease, strongly associated with a higher level of a number of cytokines, such as isoforms of transforming growth factor β (TGF-β1–3) and its receptors (TGF-βRI–III). One of the most popular and important drugs used to treat this disease is cyclosporin A (CsA).
Aim
The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of TGF-β1–3 and its receptors TGF-βRI–III as the supplementary molecular markers of lost sensitivity to the medicine.
Material and methods
The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of TGF-β1-3 and TGF-βRI-III were performed by real-time quantitative reverse transcription PCR (RTqPCR).
Results
The expression of TGF-β1-3 and TGF-βRI-III were detected in the whole period of therapy with CsA. Changes in transcriptional activities of TGF-β1–3 and TGF-βRI–III during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.
Conclusions
The changes in expression profiles of TGF-β1-3 and TGF-βRI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.
Keywords :
mRNA , transforming growth factor β1–3 , psoriasis , cyclosporin A
